Valuation: Bicycle Therapeutics plc

Market Cap 286M 251M 232M 217M 406M 27.02B 415M 2.78B 1.08B 13.33B 1.07B 1.05B 46.3B P/E 2026 *
-1.76x
P/E 2027 * -1.95x
Enterprise Value -226M -198M -183M -171M -320M -21.31B -327M -2.2B -850M -10.52B -848M -829M -36.52B EV / Sales 2026 *
-12.4x
EV / Sales 2027 * -8.36x
Free-Float
6.21%
Yield 2026 *
-
Yield 2027 * -
1 day+2.24%
1 week+2.50%
Current month-12.58%
1 month-10.28%
3 months-4.87%
6 months-39.88%
Current year-42.09%
1 week 3.92
Extreme 3.92
4.19
1 month 3.92
Extreme 3.92
4.74
Current year 3.92
Extreme 3.92
7.34
1 year 3.92
Extreme 3.92
9.18
3 years 3.92
Extreme 3.92
28.67
5 years 3.92
Extreme 3.92
62.08
10 years 3.92
Extreme 3.92
62.08
Manager TitleAgeSince
Chief Executive Officer 57 31/08/2015
Director of Finance/CFO 46 28/01/2026
Chief Tech/Sci/R&D Officer - 31/05/2025
Director TitleAgeSince
Director/Board Member 57 31/08/2015
Director/Board Member 63 16/03/2021
Director/Board Member 69 19/02/2024
Date Insider Type Main position Quantity % Market Cap.
04-01Sell

Chief Operating Officer

1,408 0.0037%
04-01Sell

Chief Executive Officer

7,683 0.0202%
04-01Sell

CHIEF PROD & SUPPLY CHAIN OFF

1,772 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
+2.24%+2.50%-43.37%-83.18% 286M
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average +0.33%+4.55%+33.81%+106.83% 22.66B
Weighted average by Cap. +0.27%+5.13%+48.38%+122.41%

Financials

2026 *2027 *
Net sales 18.24M 16.02M 14.77M 13.82M 25.88M 1.72B 26.45M 177M 68.62M 850M 68.48M 66.97M 2.95B 14.11M 12.4M 11.43M 10.7M 20.03M 1.33B 20.47M 137M 53.11M 657M 53M 51.83M 2.28B
Net income -154M -135M -124M -116M -218M -14.5B -223M -1.49B -578M -7.16B -577M -564M -24.86B -162M -143M -132M -123M -230M -15.32B -235M -1.58B -611M -7.56B -610M -596M -26.26B
Net Debt -512M -450M -415M -388M -727M -48.32B -743M -4.98B -1.93B -23.85B -1.92B -1.88B -82.82B -404M -355M -327M -306M -574M -38.15B -586M -3.93B -1.52B -18.83B -1.52B -1.48B -65.38B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
26/06/26 US$4.100 +2.24% 843,360
25/06/26 US$4.010 +1.26% 504,336
24/06/26 US$3.960 -1.00% 401,757
23/06/26 US$4.000 +0.50% 405,632
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.100USD
Average target price
12.62USD
Spread / Average Target
+207.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock